在口服治疗中病情恶化的肺动脉高压患者中添加前列腺素类药物。
Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy.
作者信息
Jacobs Wouter, Boonstra Anco, Marcus J Tim, Postmus Pieter E, Vonk-Noordegraaf Anton
机构信息
Department of Pulmonology, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The Netherlands.
出版信息
J Heart Lung Transplant. 2009 Mar;28(3):280-4. doi: 10.1016/j.healun.2008.12.003.
BACKGROUND
The aim of our study was to describe the efficacy of addition of intravenous or subscutaneous prostanoids in idiopathic pulmonary arterial hypertension (PAH) patients deteriorating on bosentan or on bosentan-sildenafil.
METHODS
PAH treatment at our hospital is standardized with first-line oral therapy in New York Heart Association class III patients followed by addition of prostanoids on clinical worsening.
RESULTS
Mean improvement in 6-minute walk distance after 4 months of prostanoids was 86 m (p < 0.01) in the bosentan group versus 41 m (p < 0.05) in the bosentan-sildenafil group, and these improvements persisted at long-term follow-up.
CONCLUSIONS
From these results we conclude that addition of subcutaneous or intravenous prostanoids can be efficacious in PAH deteriorating on oral therapy.
背景
我们研究的目的是描述在波生坦或波生坦 - 西地那非治疗下病情恶化的特发性肺动脉高压（PAH）患者中，添加静脉或皮下前列腺素类药物的疗效。
方法
我院对纽约心脏协会III级患者采用一线口服疗法对PAH进行标准化治疗，临床病情恶化时添加前列腺素类药物。
结果
在波生坦组中，使用前列腺素类药物4个月后，6分钟步行距离的平均改善为86米（p < 0.01），而在波生坦 - 西地那非组中为41米（p < 0.05），并且这些改善在长期随访中持续存在。
结论
从这些结果我们得出结论，在口服治疗病情恶化的PAH患者中添加皮下或静脉前列腺素类药物可能有效。
Zotero 插件